Becton, Dickinson and Company $BDX Shares Sold by Koshinski Asset Management Inc.

Koshinski Asset Management Inc. decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,361 shares of the medical instruments supplier’s stock after selling 63 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $1,096,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in BDX. Northcape Wealth Management LLC lifted its stake in Becton, Dickinson and Company by 0.5% in the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock valued at $2,248,000 after buying an additional 51 shares during the last quarter. Diversified Trust Co increased its holdings in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock valued at $272,000 after acquiring an additional 53 shares during the period. Bill Few Associates Inc. raised its position in Becton, Dickinson and Company by 0.7% in the 2nd quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock valued at $1,362,000 after purchasing an additional 55 shares during the last quarter. Horizon Bancorp Inc. IN boosted its stake in shares of Becton, Dickinson and Company by 10.9% during the first quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier’s stock worth $130,000 after buying an additional 56 shares during the period. Finally, Meadow Creek Wealth Advisors LLC grew its stake in shares of Becton, Dickinson and Company by 5.4% in the 1st quarter. Meadow Creek Wealth Advisors LLC now owns 1,161 shares of the medical instruments supplier’s stock valued at $266,000 after purchasing an additional 59 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 1,838 shares of company stock worth $348,392 over the last quarter. 0.36% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Morgan Stanley raised their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Argus increased their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $211.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $189.20 on Friday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The company’s 50-day moving average price is $190.60 and its 200 day moving average price is $184.63. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The stock has a market cap of $54.23 billion, a price-to-earnings ratio of 34.03, a PEG ratio of 1.48 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were given a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is currently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.